The vemurafenib-resistant melanoma cell line C3 SKMEL-239 produces BRAF exon 3^9 splicing and contains two intronic point-mutations at positions -435 (C-to-A) and -51 (C-to-G) from the BRAF intron 8 3′ splice site. Here, BRAF is linked to melanoma.